Baltimore, MD; Los Angeles-Long Beach, CA; Orange County, CA; Washington, DC; Bethesda-Freder (PRWEB) February 16, 2016 -- Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, launched a pioneering genetic profile to help physicians treat patients who are seeking medically assisted treatment (MAT) for opioid dependence. As an under-reported epidemic, prescription drug abuse is responsible for nearly three times as many deaths as illegal drugs. In an effort to combat the problem, the Proove Medically Assisted Treatment (MAT™) profile is designed to predict how patients are likely to respond to medications used to treat opioid addiction.
The profile evaluates 27 genetic markers to assess patient response to methadone and buprenorphine/naloxone—two commonly used prescriptions in medically assisted withdrawal programs. A study with 178 patients, which was published in BioMed Research International, confirmed that genes in the Proove MAT™ profile influence how a person responds to methadone. In a separate study, which was conducted by Macquarie University in Sydney, Australia, and published in Drug Metabolism & Disposition, suggested that a genetic variant impairs suboxone signaling in certain patients. By evaluating multiple genes in the Proove MAT™ profile, Proove Biosciences is able to help doctors understand how different patients are likely to respond drug detoxification.
“Proove is on a mission to fundamentally change the way doctors and patients make healthcare decisions—and it starts with providing the proof required to improve prescribing decisions,” said Brian Meshkin, CEO at Proove Biosciences. “By evaluating the factors underlying an individual’s response to medications like suboxone and methadone, for example, we are able to help physicians make the right choices about which medications to prescribe. In addition, we can help them identify which doses are likely to yield the best results—and we can do this prior to treatment.”
In the past, prescribing guidelines were limited to an assessment of behavioral, psychological, and environmental factors. With this new profile, doctors are able to incorporate genetics into the decision-making process. By using an objective tool, physicians are able to increase efficacy while minimizing withdrawal symptoms and adverse side effects. The profile could be an indispensable tool for physicians looking to adopt a precision-based approach to prescribing. By understanding how patients are likely to respond to treatment beforehand, the profile is expected to play an important role in addressing the healthcare burden of prescription drug abuse and its treatment.
About Proove Biosciences
Our mission is to change the future of medicine. Proove represents the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could have ever prescribed medications without knowing how a patient would respond. Physicians use Proove Biosciences testing to improve outcomes—both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
Public Relations, Proove Biosciences, http://www.proove.com, +1 949-556-7239, [email protected]